These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
380 related articles for article (PubMed ID: 10717621)
1. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II. Kahán Z; Sun B; Schally AV; Arencibia JM; Cai RZ; Groot K; Halmos G Cancer; 2000 Mar; 88(6):1384-92. PubMed ID: 10717621 [TBL] [Abstract][Full Text] [Related]
2. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma. Koppán M; Halmos G; Arencibia JM; Lamharzi N; Schally AV Cancer; 1998 Oct; 83(7):1335-43. PubMed ID: 9762934 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095. Miyazaki M; Lamharzi N; Schally AV; Halmos G; Szepeshazi K; Groot K; Cai RZ Eur J Cancer; 1998 Apr; 34(5):710-7. PubMed ID: 9713279 [TBL] [Abstract][Full Text] [Related]
4. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes. Bajo AM; Schally AV; Krupa M; Hebert F; Groot K; Szepeshazi K Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3836-41. PubMed ID: 11891317 [TBL] [Abstract][Full Text] [Related]
5. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095. Halmos G; Schally AV Proc Natl Acad Sci U S A; 1997 Feb; 94(3):956-60. PubMed ID: 9023364 [TBL] [Abstract][Full Text] [Related]
6. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II. Szepeshazi K; Schally AV; Rick FG; Block NL; Vidaurre I; Halmos G; Szalontay L Anticancer Drugs; 2012 Oct; 23(9):906-13. PubMed ID: 22926257 [TBL] [Abstract][Full Text] [Related]
7. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342 [TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice. Yano T; Pinski J; Szepeshazi K; Halmos G; Radulovic S; Groot K; Schally AV Cancer; 1994 Feb; 73(4):1229-38. PubMed ID: 8313327 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix. Chatzistamou I; Schally AV; Szepeshazi K; Groot K; Hebert F; Arencibia JM Cancer Lett; 2001 Sep; 171(1):37-45. PubMed ID: 11485826 [TBL] [Abstract][Full Text] [Related]
10. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Jungwirth A; Galvan G; Pinski J; Halmos G; Szepeshazi K; Cai RZ; Groot K; Schally AV Prostate; 1997 Aug; 32(3):164-72. PubMed ID: 9254895 [TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-II and RC-3095 on MCF-7 MIII human breast cancer xenografts in nude mice. Shirahige Y; Cai RZ; Szepeshazi K; Halmos G; Pinski J; Groot K; Schally AV Biomed Pharmacother; 1994; 48(10):465-72. PubMed ID: 7858155 [TBL] [Abstract][Full Text] [Related]
12. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Pinski J; Halmos G; Szepeshazi K; Schally AV Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists. Chatzistamou I; Schally AV; Sun B; Armatis P; Szepeshazi K Br J Cancer; 2000 Oct; 83(7):906-13. PubMed ID: 10970693 [TBL] [Abstract][Full Text] [Related]
14. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. Plonowski A; Schally AV; Varga JL; Rekasi Z; Hebert F; Halmos G; Groot K Prostate; 2000 Jul; 44(2):172-80. PubMed ID: 10881027 [TBL] [Abstract][Full Text] [Related]
15. Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice. Pinski J; Schally AV; Halmos G; Szepeshazi K; Groot K; O'Byrne K; Cai RZ Br J Cancer; 1994 Nov; 70(5):886-92. PubMed ID: 7947094 [TBL] [Abstract][Full Text] [Related]
16. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095. Szepeshazi K; Schally AV; Halmos G; Groot K; Radulovic S J Natl Cancer Inst; 1992 Dec; 84(24):1915-22. PubMed ID: 1460673 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Kanashiro CA; Schally AV; Groot K; Armatis P; Bernardino AL; Varga JL Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15836-41. PubMed ID: 14660794 [TBL] [Abstract][Full Text] [Related]
18. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. Rick FG; Buchholz S; Schally AV; Szalontay L; Krishan A; Datz C; Stadlmayr A; Aigner E; Perez R; Seitz S; Block NL; Hohla F Cell Cycle; 2012 Jul; 11(13):2518-25. PubMed ID: 22751419 [TBL] [Abstract][Full Text] [Related]
19. Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters. Szepeshazi K; Schally AV; Groot K; Halmos G Int J Cancer; 1993 May; 54(2):282-9. PubMed ID: 8387464 [TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice. Radulovic S; Schally AV; Reile H; Halmos G; Szepeshazi K; Groot K; Milovanovic S; Miller G; Yano T Acta Oncol; 1994; 33(6):693-701. PubMed ID: 7946450 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]